ADA

ADA 2024: Inhaled insulin meets primary efficacy endpoints in T1DM study

June 25, 2024

Findings from the INHALE-3 study, which compared the efficacy of an inhaled insulin regimen plus degludec insulin (Tresiba) against usual care over 17 weeks, showed that inhaled insulin could provide an alternative insulin solution for diabetes management.

• 120 participants with T1DM using multiple daily injections, automated insulin delivery (AID) devices, and continuous glucose monitoring (CGM) were randomly assigned to either insulin degludec plus inhaled insulin Afrezza and CGM or continuation of usual care. The primary outcome of the trial was at 17 weeks. The primary endpoint was change in A1c levels; secondary endpoints included changes in time-in-range (TIR) and hypoglycemia measured via CGM and patient reported outcomes on insulin delivery satisfaction.
• More participants using the inhaled insulin regimen experienced significant improvements in A1C levels compared with those on usual care: 21% of participants using inhaled insulin had an A1C improvement >0.5%, while only 5% undergoing standard care saw an improvement.
• 19% of participants who switched from using an AID system to using inhaled insulin plus degludec achieved an A1C improvement >0.5%.
• In contrast, 26% of the patients in the inhaled insulin group had a worsening of A1C >0.5% compared with 3% with standard care, suggesting that inhaled insulin plus degludec isn't appropriate for all patients.

Sources:

(2024, June 22). American Diabetes Association. Study shows promising results for inhaled insulin as treatment for type 1 diabetes. [Press release]. https://diabetes.org/newsroom/press-releases/study-shows-promising-results-inhaled-insulin-treatment-type-1-diabetes

(2024, June 22). ADA Meeting News. INHALE-3 investigators detail benefits of inhaled insulin for type 1 diabetes. https://www.adameetingnews.org/inhale-3-investigators-detail-benefits-of-inhaled-insulin-for-type-1-diabetes/